Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) (Q28182735)
Jump to navigation
Jump to search
scientific article (publication date: October 2003)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) |
scientific article (publication date: October 2003) |
Statements
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) (English)
0 references
Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) (English)
Marc A. Pfeffer
Theressa J. Wright
MOXCON Investigators
October 2003
0 references
5
0 references
659-67
0 references
5
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference